Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)
Status:
Completed
Trial end date:
2020-05-26
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, vehicle-controlled Phase 3 study to evaluate the efficacy
and safety of topical tapinarof cream, 1% once daily for the treatment of plaque psoriasis in
adults. Approximately 500 adult subjects with plaque psoriasis will be randomized 2:1 to
receive either tapinarof cream, 1% or matching vehicle cream once daily for 12 weeks.